Search

Displaying results 3641 - 3650 of 8700 in total
  1. Drug

    PF-03814735

    go.drugbank.com/drugs/DB13059
    Investigational

    PF-03814735 has been used in trials studying the treatment of Solid Tumors.

  2. Drug

    Levomilnacipran

    go.drugbank.com/drugs/DB08918
    ApprovedInvestigational

    [L47956] While levomilnacipran was previously investigated and proposed as a potential treatment for stroke in Europe, the EMA decided against this use.[L48011]

    Categories: Antidepressive Agents Indicated for Depression, P-glycoprotein substrates
  3. Drug

    Paliroden

    go.drugbank.com/drugs/DB05454
    Investigational

    It is indicated for use in Alzheimer's Disease and Parkinson’s. … Paliroden is an orally active neurotrophic, non-peptidic compound that activates synthesis of endogenous neurotrophines.

  4. Drug

    Flunarizine

    go.drugbank.com/drugs/DB04841
    ApprovedInvestigational

    It is effective in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and peripheral origin, and as an adjuvant in the therapy of epilepsy.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A1 Substrates
  5. Drug

    Tromantadine

    go.drugbank.com/drugs/DB13288
    Approved

    It is an antiviral used in the treatment of herpes zoster and simplex.

    Categories: Antivirals for Systemic Use, Antiinfectives for Systemic Use
  6. Drug

    Zidesamtinib

    go.drugbank.com/drugs/DB21623
    ApprovedInvestigational

    [L63808,L63933] Zidesamtinib is selective for ROS1, retains activity in cells carrying the common resistance mutations, and showed antitumor activity in an intracranial model, positioning it for use after … another ROS1 inhibitor has failed rather than as an alternative first choice.

  7. Drug

    Garadacimab

    go.drugbank.com/drugs/DB15629
    Approved

    [A273993,A273998] As opposed to [lanadelumab], another prophylactic agent for HAE that targets kallikrein, garadacimab targets activated factor XII, the first factor in the contact system responsible for … [A273993] In June 2025, garadacimab was approved by the US FDA for the prophylaxis of HAE episodes in patients ≥12 years of age.

  8. Drug

    Florbetaben F-18

    go.drugbank.com/drugs/DB09148
    ApprovedInvestigational

    Florbetaben is a fluorine-18 (18F)-labeled stilbene derivative used for Positron Emission Tomography (PET) imaging of the brain. … This radioactive diagnostic drug is used for the non-invasive detection of the density of beta-amyloid plaques in the brain of adult patients with cognitive impairment.[A18514, L53703]

  9. Drug

    Vutrisiran

    go.drugbank.com/drugs/DB16699
    ApprovedInvestigational

    [A249010] More than 130 TTR mutations have been identified so far,[A249015] but the most common one is the replacement of valine with methionine at position 30 (Val30Met). … [A249025,L42065] This delivery platform gives vutrisiran high potency and metabolic stability, and allows for subcutaneous injections to take place once every three months.

  10. Drug

    Bazedoxifene

    go.drugbank.com/drugs/DB06401
    ApprovedInvestigational

    In late 2013, Pfizer received approval for bazedoxifene as part of the combination drug DUAVEE in the prevention (not treatment) of postmenopausal osteoporosis. … In 2013, the combination product containing conjugated estrogens and bazedoxifene was approved by the FDA for the treatment of moderate to severe vasomotor symptoms associated with menopause, as well as

    Categories: Estrogen Receptor Modulators, Selective Estrogen Receptor Modulators